ENTRADA THERAPEUTICS, INC. Comprehensive Income
ENTRADA THERAPEUTICS, INC. (TRDA) reported Comprehensive Income of -$42.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:ComprehensiveIncomeNetOfTax · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-06-30 was -$42.94M.
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2026-03-31 was -$40.12M.
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-12-31 was -$39.13M, a 33835.34% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for the quarter ending 2025-09-30 was -$43.91M.
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2025 was -$143.06M, a 318.78% decline from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2024 was $65.39M.
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2023 was -$4.43M.
- ENTRADA THERAPEUTICS, INC. comprehensive income (loss), net of tax, attributable to parent for fiscal 2022 was -$96.67M.
| Period end | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 3 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 6 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 9 month | Comprehensive Income (Loss), Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.94M 10-Q · filed 2026-08-05 | -$83.07M 10-Q · filed 2026-08-05 | -$122.20M derived: sum of 3 quarters · filed 2026-08-05 | -$166.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$40.12M 10-Q · filed 2026-05-07 | -$79.26M derived: sum of 2 quarters · filed 2026-05-07 | -$123.17M derived: sum of 3 quarters · filed 2026-05-07 | -$166.31M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | -$39.13M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$83.05M derived: sum of 2 quarters · filed 2026-02-26 | -$126.19M derived: sum of 3 quarters · filed 2026-08-05 | -$143.06M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$43.91M 10-Q · filed 2025-11-06 | -$87.05M derived: sum of 2 quarters · filed 2026-08-05 | -$103.92M 10-Q · filed 2025-11-06 | -$103.81M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$43.14M 10-Q · filed 2026-08-05 | -$60.01M 10-Q · filed 2026-08-05 | -$59.89M derived: sum of 3 quarters · filed 2026-08-05 | -$72.62M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$16.87M 10-Q · filed 2026-05-07 | -$16.75M derived: sum of 2 quarters · filed 2026-05-07 | -$29.48M derived: sum of 3 quarters · filed 2026-05-07 | $25.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $116.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$12.62M derived: sum of 2 quarters · filed 2026-02-26 | $42.33M derived: sum of 3 quarters · filed 2026-02-26 | $65.39M 10-K · filed 2026-02-26 |
| 2024-09-30 | -$12.73M 10-Q · filed 2025-11-06 | $42.22M derived: sum of 2 quarters · filed 2025-11-06 | $65.27M 10-Q · filed 2025-11-06 | $56.42M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $54.95M 10-Q · filed 2025-08-06 | $78.00M 10-Q · filed 2025-08-06 | $69.15M derived: sum of 3 quarters · filed 2025-08-06 | $105.12M derived: sum of 4 quarters · filed 2025-08-06 |
| 2024-03-31 | $23.05M 10-Q · filed 2025-05-08 | $14.20M derived: sum of 2 quarters · filed 2025-05-08 | $50.17M derived: sum of 3 quarters · filed 2025-05-08 | $23.88M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | -$8.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $27.12M derived: sum of 2 quarters · filed 2025-02-27 | $826.00K derived: sum of 3 quarters · filed 2025-02-27 | -$4.43M 10-K · filed 2025-02-27 |
| 2023-09-30 | $35.97M 10-Q · filed 2024-11-05 | $9.68M derived: sum of 2 quarters · filed 2024-11-05 | $4.42M 10-Q · filed 2024-11-05 | -$19.52M derived: sum of 4 quarters · filed 2024-11-05 |
| 2023-06-30 | -$26.29M 10-Q · filed 2024-08-13 | -$31.55M 10-Q · filed 2024-08-13 | -$55.49M derived: sum of 3 quarters · filed 2024-08-13 | -$81.11M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$5.26M 10-Q · filed 2024-05-07 | -$29.20M derived: sum of 2 quarters · filed 2024-05-07 | -$54.82M derived: sum of 3 quarters · filed 2024-05-07 | -$78.73M derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | -$23.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | -$49.56M derived: sum of 2 quarters · filed 2024-03-13 | -$73.47M derived: sum of 3 quarters · filed 2024-03-13 | -$96.67M 10-K · filed 2024-03-13 |
| 2022-09-30 | -$25.62M 10-Q · filed 2023-11-07 | -$49.53M derived: sum of 2 quarters · filed 2023-11-07 | -$72.73M 10-Q · filed 2023-11-07 | -$91.18M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | -$23.91M 10-Q · filed 2023-08-08 | -$47.12M 10-Q · filed 2023-08-08 | -$65.56M derived: sum of 3 quarters · filed 2023-08-08 | -$79.99M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | -$23.21M 10-Q · filed 2023-05-10 | -$41.65M derived: sum of 2 quarters · filed 2023-05-10 | -$56.08M derived: sum of 3 quarters · filed 2023-05-10 | -$65.98M derived: sum of 4 quarters · filed 2023-05-10 |
| 2021-12-31 | -$18.45M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-06 | -$32.88M derived: sum of 2 quarters · filed 2023-03-06 | -$42.78M derived: sum of 3 quarters · filed 2023-03-06 | -$51.16M 10-K · filed 2023-03-06 |
| 2021-09-30 | -$14.43M 10-Q · filed 2022-11-07 | -$24.33M derived: sum of 2 quarters · filed 2022-11-07 | -$32.71M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | -$9.90M 10-Q · filed 2022-08-11 | -$18.28M 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | -$8.38M 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |